MEB Medibio

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health

SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited  (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.

The mobile app, named Medibio Inform, allows businesses to offer employees the chance to ‘check-in on their mental health’ through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. This allows employees of participating businesses using Fitbit devices to assess their mental health using both traditional assessments and biometric measures.  At this time, only Fitbit users that are enrolled in a Mental Health Check-In with their employer have access to use the Inform app.

Via the Inform app, Fitbit users will be able to process specific biometric features to create an objective view of their overall health. Once the user has authorized Medibio to access their Fitbit account, the Inform app then pulls in the sleep, activity and heart rate data that is associated with the user’s wearable account. Medibio uses its proprietary platform and algorithms to process the biometric data and reports to the user on a daily basis.

The additional compatibility of Inform working with data from more than 25 million Fitbit wearable technologies, along with already accepted compatibility with nearly 13 million Garmin devices, is timely as the company prepares for the general consumer availability coming later in 2018. 

“We’re thrilled to give Fitbit users the ability to monitor their personal, objective biometric data to help manage their overall mental health and well-being,” said Jack Cosentino, CEO of Medibio. “With the addition of Fitbit to our portfolio of compatible wearables, this strengthens our footprint in the market, and supports our goal to make our technology accessible to as many consumers as possible.”

Medibio’s Fitbit-compatible app is available in the App Store and Google Play today for compatible Fitbit devices.   For more information, visit the company’s website at .

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Perth (WA), and Minneapolis, MN (U.S.). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on and .

Further Information: 



 
 Website:
Press Inquiries:

Josh Purdy

Medibio Limited



T: 952-222-0551 ext. 204

M: 612-695-0168
Australian Media Enquiries:

Nicholas Hay

RES Publica



T: //

EN
13/06/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medibio

 PRESS RELEASE

Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclus...

Medibio Signs Insurance Company AIA Australia Ltd (AIAA) For an Exclusive Pilot Program For ilumen™ SYDNEY, Australia and MINNEAPOLIS, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces that it has signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers, offering a range of products that protect the financial health and wellbeing of more than 4 million Australians.  AIAA is ...

 PRESS RELEASE

Medibio Appoints Global Healthcare & Medical Device Leader as CEO and ...

Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director SYDNEY, Australia and MINNEAPOLIS, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announces the appointment of David B. Kaysen as CEO and Managing Director. Mr. Kaysen brings more than 35 years of experience leading and managing both domestic and international emerging growth companies. He has achieved consistent and solid results with bio-pharmaceutical, medical device, and clinical software/IT companies. He is exper...

 PRESS RELEASE

Medibio Market Update

Medibio Market Update SYDNEY, Australia and MINNEAPOLIS, Minn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today shares a market update to the recent quarterly update. ISO 13485 CertificationThis week the company completed the annual audit process for certification of the Company’s Quality Management System.  The audit was conducted by DQS Med, the Notified Body appointed to assess our compliance. There were no major or minor findings, providing further evidence of the stability of our quality s...

 PRESS RELEASE

Medibio Limited Quarterly ASX Update and Cashflows

Medibio Limited Quarterly ASX Update and Cashflows Quarterly Update and Message from Medibio Limited SYDNEY, Australia and MINNEAPOLIS, Minn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF), a mental health technology company provides the following quarterly update: Key highlights from the quarter Announced clinical study results - showing an improvement of more than 20% to current diagnostic standard- Achievement of 70% accuracy, 70% sensitivity and 71% specificity results - demonstrating utility as diagnostic aide and long-term monitor...

 PRESS RELEASE

Medibio Signs ilumenâ„¢ Corporate Contract with a Large Australian Em...

Medibio Signs ilumen™ Corporate Contract with a Large Australian Employer SYDNEY, Australia and MINNEAPOLIS, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company, announces a contract for the latest release of its corporate health program, ilumen™. ilumen™ is unique to the corporate health market as it integrates unique and proprietary objective biometrics with subjective assessments. Users can access and monitor this data from their personal devices, measuring and tracking biometrics through the use of wear...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch